TOKYO, May 18 (Pulse News Wire) – RIBOMIC Inc. (4591.T) reported its financial results for the quarter ended March 2026.
Operating profit improved to 1,207 million yen compared to a loss of 1,050 million yen in the previous fiscal year, driven by increased revenue from technology provision related to drug delivery systems (DDS). Research and development expenses rose to 803 million yen due to ongoing clinical trials for RBM-007 and RBM-006. The company also completed Phase 2 proof-of-concept studies for RBM-007 and initiated Phase 3 trials for the treatment of achondroplasia (ACH).
Additionally, RBM-007 received orphan drug designation from the Ministry of Health, Labour and Welfare in May 2025, enabling the firm to secure additional funding up to half of eligible research costs over three fiscal years. As of March 2026, total assets stood at ¥2.976 billion, while liabilities decreased by 7 million yen year-over-year. Total equity increased by ¥942 million due to the exercise of subscription rights and capital raising activities.
In related developments, RIBOMIC secured approximately ¥920.0 million through the issuance of subscription warrants to EVO FUND, aimed at financing Phase 3 trials for RBM-007 and general operating funds.
🟢 Confidence: High AI-translated content.